Cladribine Tablets: Observational Evaluation Of Effectiveness And Patient-Reported Outcomes (Pros) In Suboptimally Controlled Patients Previously Taking Oral Or Infusion Disease Modifying Drugs (Dmds) For Relapsing Forms Of Multiple Sclerosis (RMS) (MASTER-2)

The purpose of the MASTER-2 study is to evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal response to any oral or infusion Disease-Modifying Drugs (DMDs) approved in the United States (US) for RMS in a real-world-setting.